Office of Life Sciences welcomed by UK firms

5 April 2009

The UK BioIndustry Association has welcomed the government's decision to set up an Office for Life Sciences. The biotechnology manufacturer's  group stated that "the establishment of OLS is a positive and  much-needed development and a new way for government and industry to  work collaboratively to secure the future of what should be one of the  UK's most promising sectors."

Recently, the BIA had highlighted the capital challenges that the UK  life sciences sector faces in the current economic situation and called  for swift government action "to reinvigorate the investment environment"  for small- and medium-sized enterprises (Marketletter April 6). The BIA  believes that the OLS is the mechanism to deliver results, provided it  can do so rapidly.

Many of the required initiatives were outlined in the Bioscience  Innovation and Growth Team's Review and Refresh of Bioscience 2015,  published in January. These include:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight